Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3408/10/20: Anonymous non-contactable v Amgen (Blincyto) – No breach (prescribing information alleged out of date)

Anonymous complaint alleged Blincyto detail aid prescribing information was incorrect/out of date. Panel found complainant provided no supporting…

8 Mar 2026

AUTH/3476/2/21: Anonymous (contactable) v Leo Pharma – LinkedIn profile allegations (No breach after appeal)

Complaint alleged a Leo employee’s LinkedIn CV-style β€œExperience” section promoted medicines and used β€œsafe” improperly. Panel found some…

8 Mar 2026

Thornton & Ross webinar invite: sponsorship not clear at the outset (AUTH/3577/11/21)

A webinar invitation email appeared to come from an independent organisation and did not mention Thornton & Ross.…

8 Mar 2026

Accord: representative provided Methofill training devices without flagging paediatric Crohn’s use was off-label (AUTH/3682/8/22)

A rep supplied Methofill injector training materials to a children’s gastroenterology nurse without immediately stating paediatric Crohn’s use…

8 Mar 2026

ALK-AbellΓ³: Representative’s Facebook post promoted Jext (POM) to the public

An ALK-AbellΓ³ representative posted about Jext on Facebook with a link to the product website and urged people…

8 Mar 2026

AUTH/3829/9/23: Complainant v GSK β€” event website sponsorship declaration (no breach)

Complaint alleged GSK sponsorship of an HCP event wasn’t disclosed on the homepage or registration pages. Panel found…

8 Mar 2026

AUTH/3239/8/19: Pharmacist v Colonis Pharma Limited – promotion of Melatonin Oral Solution and off-label implication

A pharmacist complained a launch letter promoted off-label use of Melatonin 1mg/ml Oral Solution. The Panel ruled the…

8 Mar 2026

AUTH/2115/4/08 Roche v GlaxoSmithKline: Press releases for Tykerb/Tyverb (lapatinib) on corporate website

Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel found one release misleading on adverse…

8 Mar 2026

Allergan v Merz Pharma (AUTH/2270/10/09): β€œAt least as effective as Botox” claim from non-inferiority studies ruled misleading

Merz promoted Xeomin as β€œAt least as effective as Botox with a similar safety profile” on an exhibition…

8 Mar 2026

AUTH/2311/4/10: Anonymous v AstraZeneca – Seroquel meeting alleged off-label promotion (No breach)

Anonymous alleged an AstraZeneca meeting misled attendees and promoted Seroquel for borderline personality disorder. Panel found no evidence…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training